Detalhe da pesquisa
1.
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell
; 185(3): 563-575.e11, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35120664
2.
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.
Nat Immunol
; 23(8): 1183-1192, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35902637
3.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
N Engl J Med
; 388(19): 1767-1778, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163623
4.
Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.
Cancer
; 130(5): 692-701, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864521
5.
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Lancet
; 401(10379): 821-832, 2023 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774933
6.
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
Oncologist
; 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38280218
7.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657295
8.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med
; 384(14): 1289-1300, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33616314
9.
Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study.
BJU Int
; 133(2): 169-178, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589200
10.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
J Natl Compr Canc Netw
; 22(1): 4-16, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394781
11.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858721
12.
Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.
Cancer
; 129(24): 3952-3961, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37715631
13.
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.
Oncologist
; 28(6): 501-509, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36866412
14.
Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive Nephrectomy.
J Urol
; 210(2): 273-279, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37167628
15.
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy.
Future Oncol
; 19(2): 113-121, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36752726
16.
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(2): 292-303, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35032437
17.
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Lancet Oncol
; 23(6): 768-780, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489363
18.
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(7): 888-898, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35688173
19.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383908
20.
Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New Challenges.
N Engl J Med
; 390(15): 1432-1433, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38631007